Andy Studna

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

In a recent video interview with Applied Clinical Trials, Krinx Kong, chief commercial officer, Cognivia, discussed the potential impacts of policy shifts on vaccine trial design and patient perceptions. Stricter regulations could increase trial complexity, affecting recruitment and retention. Kong emphasized behavioral insights as crucial to understanding patient motivation and mitigating dropouts.

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

In a recent video interview with Applied Clinical Trials, Krinx Kong, chief commercial officer, Cognivia, discussed the potential impacts of policy shifts on vaccine trial design and patient perceptions. Stricter regulations could increase trial complexity, affecting recruitment and retention. Kong emphasized behavioral insights as crucial to understanding patient motivation and mitigating dropouts.

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

Boehringer Ingelheim has announced the start of the JADE Phase II clinical trial (NCT06769048), evluating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for geographic atrophy (GA). BI 1584862, a phospholipid modulator, was discovered and developed in-house by Boehringer.

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

Gilead has announced final data from its Phase III MYR301 clinical trial of bulevirtide in patients with chronic hepatitis delta virus (HDV). At either a 2 mg or 10 mg dose, the first-in-class entry inhibitor maintained virologic suppression for almost two years following treatment after achieving undetectable HDV RNA at end of treatment in 36% of adults living with HDV who were treated.

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

May 7, 2025By In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.